Actively Recruiting
Elevated Rate Pacing of Cardiac Amyloidosis Personalized Pacemaker Protocol to Study Heart Failure Symptoms and Exercise Tolerance
Led by University of Minnesota · Updated on 2026-05-13
10
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating how heart failure symptoms and exercise tolerance change before and after increasing heart rate in patients with cardiac amyloidosis who already have pacemakers. This study focuses on a small group of 10 patients to better understand these improvements in their condition. Participants with cardiac amyloidosis and pacemakers will receive a personalized pacing protocol tailored to their height and heart function, specifically their left ventricular ejection fraction. This individualized pacing adjustment is designed to elevate the heart rate and assess its effects. During the study, researchers will measure heart failure symptoms using the Kansas City Cardiomyopathy Questionnaire and track any cardiovascular events over four months. Participants will be monitored closely, with assessments focused on heart function and symptom changes throughout the study period.
CONDITIONS
Brief Title
Elevated Rate Pacing of Cardiac Amyloidosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years and older
- Diagnosis of cardiac amyloidosis according to established clinical guidelines
- Implanted cardiac pacemaker or defibrillator
- Pacemaker mode of AAI or DDD if in sinus rhythm, VVI if permanent atrial fibrillation
- Non-dilated left ventricle by echocardiography
- Ability to provide written consent
- English speaking
You will not qualify if you...
- Paced QRS duration greater than 150 ms indicating pacing mediated dyssynchrony
- Dilated left ventricle
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - Up to 4 months
Participants with cardiac amyloidosis and implanted pacemakers receive a personalized pacing protocol tailored to their height and heart function.
Regular visits to adjust and monitor pacemaker settings
Duration - Up to 4 months
Participants are monitored for heart failure symptoms and cardiovascular events after the treatment protocol.
Follow-up visits to assess outcomes
Trial Site Locations
Total: 1 location
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
Research Team
M
Meghan Muscala
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here